Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma - Wikidata - wikimedia - TriplyDB

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

http://www.wikidata.org/entity/Q24685080

about

Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer Beyond CA125: the coming of age of ovarian cancer biomarkers Mesothelin expression in the leptomeninges and meningiomas Characterization of human mesothelin transcripts in ovarian and pancreatic cancer Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells Clinical impacts of mesothelin expression in gastrointestinal carcinomas Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis Toxin-based therapeutic approaches Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes.Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.Systematic evaluation of candidate blood markers for detecting ovarian cancer.The role of proteomics in the diagnosis and treatment of ovarian cancer.Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study A novel high-affinity human monoclonal antibody to mesothelin.Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease.Mesothelin promotes cell proliferation in the remodeling of neonatal rat pancreas.Discovery of mesothelin and exploiting it as a target for immunotherapy.CA125 in ovarian cancer Antifouling surface layers for improved signal-to-noise of particle-based immunoassays.LRRN4 and UPK3B are markers of primary mesothelial cells Origin of myofibroblasts in the fibrotic liver in mice Early detection of ovarian cancer Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy.Mesothelin as a potential therapeutic target in human cholangiocarcinoma.Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects.Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.Preoperative serum levels of mesothelin in patients with colon cancer.Identification of novel markers for the diagnosis of malignant pleural mesothelioma.

P2860

Q24651062-F77C1B62-B1BA-4485-8422-896EDA02D697 Q24651567-DA10726B-4E52-46C6-A7B1-20BF478CD175 Q24654033-BAD9B544-9296-46D6-9FCC-F30416D96AC3 Q24791193-7ED8B229-5097-43BE-95F1-61572DF86FBC Q24797540-6D457D6B-B165-4921-8015-F1CD903800FE Q26748680-0244EFF9-0250-4E24-91C6-5A8ABAD5B430 Q26860736-E93BE553-60D6-4FFF-B357-5CCC28769257 Q27013664-0D35439E-B2AC-4F1B-9F83-74279EAB5C10 Q27015134-BD30CFC1-DF6B-4836-B2A0-E9F09FAFDB8A Q28258206-EAAC1B4B-C359-44C8-80CD-E0DD23A04C2A Q28263206-598577FB-87AB-4A35-B950-AFF88AE83F55 Q28392105-5D2193CC-BC1D-47CD-B40E-7E14B7ECD2F8 Q28478285-E1825275-E116-498A-AA81-15B62287AF56 Q28547381-ED3DED0B-030D-4E32-BFAA-41371C73AAA9 Q28570727-B14515F5-25B9-410A-BCC7-699EFAB04DA9 Q29048401-AD983220-9627-4530-A813-EE48901BE545 Q30596678-69636DF1-6C2A-4CC6-8DD4-0F8E12006F7F Q30763413-3E0A8D56-A691-4D3C-A502-88BB27970849 Q31005059-6125BF20-E839-4DDC-AE32-2267E175B7CF Q33344488-7DCDD96C-4E8E-4875-B5FA-C00BB43AA9AF Q33350146-16624CAC-A263-462D-812C-0AA8B18763DC Q33508672-D960C76A-8DE6-4B14-840F-B5A7D8206BED Q33574039-83892ABE-4C9B-486E-83FE-C68D49A5D96D Q33634221-766AFA94-878D-42C6-BF22-31BAEF09AB66 Q33734661-6F59D513-B179-4E9A-A790-90A0926E54AC Q33735285-244F517C-457E-4265-9A08-53A18C448530 Q33772688-7648BADE-34CF-4A07-B56F-C79C07607F56 Q33859857-506D4770-3BCE-4955-B747-117B21EE2BB6 Q33939569-A5098287-AFA5-4D07-B5F5-B2AF488B7062 Q34044878-DCAB9BBE-AB4A-472E-ACCF-4044C1DADE90 Q34060761-C177BD25-99A0-4F6F-9664-CD5778802A1B Q34094731-9B6926E4-FF12-4E08-94C7-EB645888D1D0 Q34096881-0FEB4EE3-C3E9-4A92-9786-5D512D8ADAB8 Q34134506-5F8A56FB-46EC-4930-9358-84165C29DEE8 Q34167021-BA5043CC-2AC3-4630-8DB1-9256293B1097 Q34235597-2CB0F56F-A95B-4783-857F-12F5BFB165C7 Q34313298-75409C8D-3DD0-44C2-A33A-3A7C103F1AF9 Q34408489-5FD98152-FE3A-4172-98FE-C657F8C5DED2 Q34588560-B6BBA683-0202-4C75-A581-98B7DD36A5E7 Q34760760-D3FCA9E8-E66D-4456-A06D-5082024D3C20

P2860

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

http://www.wikidata.org/entity/Q24685080

description

1999 nî lūn-bûn

@nan

1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@ast

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@en

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@nl

type

label

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@ast

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@en

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@nl

prefLabel

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@ast

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@en

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@nl

P1433

Q24685080-86B75CD3-483F-4852-8D11-CA2C8794CBCC

P1476

Q24685080-9CCE94DF-E51C-4AEB-B5F4-8E56C83C974E

P2093

Q24685080-1CBF320C-0045-4B64-A48F-C97149EF18C3

Q24685080-5D50981D-4054-4429-9365-63B950242A49

Q24685080-79CE1702-5616-4BB3-A57A-FB324B9B892F

Q24685080-7BCA7CDD-AA19-44F6-91AD-511E80A45833

Q24685080-823CD2E3-3ED6-4DEE-8D40-2253C1DC196F

Q24685080-996609C6-6925-47A4-AA46-88D71692EA70

Q24685080-FB615EE9-E8C2-41DB-93D7-245AFC569E6B

P2860

Q24685080-0BC0E0E1-0175-4FDD-A0FF-A6224AD0BACC

Q24685080-1E6D95D9-E474-41FA-92E3-7F2E6C85C1F6

Q24685080-2BEA2C01-BEF1-4599-ABFB-D521AAF455A0

Q24685080-35764173-1405-400F-BFE6-2D9D709C7E36

Q24685080-470AABFC-1193-4B1E-81A2-FCF0419BEA60

Q24685080-54591496-04E3-4917-A2DA-FB842C54DF77

Q24685080-55A9EE69-CC75-43C1-81D1-7C8B7EE8B35A

Q24685080-6D1BD569-A5DC-4D77-A660-50354253C29E

Q24685080-8D617079-4C53-42F6-9F2E-9A55787BB0B0

Q24685080-A61F65A6-10EA-43D1-85A5-6A48F13ECF5D

P304

Q24685080-CA8C9448-4523-4A59-B127-61B17B7A885C

P31

Q24685080-202A3424-2240-40A2-B066-0A9E4269A43C

P3181

Q24685080-0943A492-D2BB-487D-B536-B1F677370F40

P356

Q24685080-11D79923-3AC6-44DE-948F-14093E67B842

P407

Q24685080-E21CE14D-6844-4FF4-9782-80B0B4544CEC

P433

Q24685080-1FF93287-D5E1-4EBD-B496-8DC9C32FBB35

P478

Q24685080-689AC566-ED7E-4794-B902-249DCC47C065

P577

Q24685080-2FC87368-0F48-4C1F-BE8D-6246EB062AC7

P5875

Q24685080-8983565F-45B7-4A50-AA93-E6FDE8326645

P698

Q24685080-88E54A3C-C5ED-4195-82EE-2F879AAEABE1

P921

Q24685080-D3E9213A-7676-43C5-A8F3-1F65E9E26491

P932

Q24685080-A28E688C-B8C5-43CE-B506-076241CB7DC7

P3181

P356

PNAS.96.20.11531

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Soluble member(s) of the mesot ...... atients with ovarian carcinoma

@en

P2093

G E Goodman

http://www.w3.org/2001/XMLSchema#string

I Hellström

http://www.w3.org/2001/XMLSchema#string

K E Hellström

http://www.w3.org/2001/XMLSchema#string

N Fu

http://www.w3.org/2001/XMLSchema#string

N Scholler

http://www.w3.org/2001/XMLSchema#string

Y Yang

http://www.w3.org/2001/XMLSchema#string

Z Ye

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium

Molecular cloning and expression of megakaryocyte potentiating factor cDNA

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.

Cell surface antigens of human melanoma identified by monoclonal antibody.

The CA 125 tumour-associated antigen: a review of the literature.

CA 72-4 serum marker--a new tool in the management of carcinoma patients.

The value of tumor markers in colorectal cancer.

Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.

P304

11531-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

491388

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.96.20.11531

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12800583

http://www.w3.org/2001/XMLSchema#string

P698

10500211

http://www.w3.org/2001/XMLSchema#string

P921

P932

18068

http://www.w3.org/2001/XMLSchema#string